Favorable benefit–risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria
Guger, Michael, Ackerl, Michael Matthias, Heine, Martin, Hofinger-Renner, Christiane, Spiss, Heinrich Karl, Taut, Andrea, Unger, Karin, Leutmezer, Fritz
Published in eNeurologicalSci (01.06.2022)
Published in eNeurologicalSci (01.06.2022)
Get full text
Journal Article